Dongwha Pharm

000020 · KOSPI · ₩000020 · 동화약품

₩5,100▼ ₩60 (1.16%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me

Valuation model · Discounted cash flow (DCF)

We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.

Fair value per share

₩4,245

vs the current price (₩5,100)

Enterprise value
₩224B
Equity value
₩119B
WACC
6.1%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.

Bear / Base / Bull

Bear
—
Base
₩4,245
−16.8%
Bull
₩24,755
+385.4%

Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.

Assumptions

Sign in to change the assumptions and see the results update. Sign in

Cycle options

Margin path

Every year uses the cycle-average margin (4.9%).

Revenue growth

  • 13.4%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (13.4% a year, annual reports), fading to 3% by year 5.

  • 10.8%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (13.4% a year, annual reports), fading to 3% by year 5.

  • 8.2%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (13.4% a year, annual reports), fading to 3% by year 5.

  • 5.6%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (13.4% a year, annual reports), fading to 3% by year 5.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (13.4% a year, annual reports), fading to 3% by year 5.

Business

  • 4.9%

    Operating profit as a share of revenue.

    Default: through-the-cycle average of the last 12 months and the last 5 annual reports' operating margins.

  • 27.5%

    Share of operating profit paid as corporate tax.

    Default: Korea's top corporate tax rate (25%) plus 10% local income tax.

  • 3.5%

    The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).

    Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).

  • 11.5%

    Money spent on factories, equipment, software and other long-term assets (% of revenue).

    Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).

  • 20.7%

    Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.

    Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 3 years.

Discount rate

  • 2%

    How fast cash flows keep growing every year after year 5.

    Default: about Korea's long-run inflation plus real growth.

  • 4.01%

    Yield on Korea's 10-year government bond: the return with almost no risk.

    Default: Korea Treasury Bond 10-year yield on 2026-10-30.

  • 0.6

    How much the share moves when the market moves: 1 means just like the market.

    Default: 104 weeks of weekly returns against KOSPI (official index); raw beta -0.01, adjusted toward 1 and kept between 0.6 and 2.0.

  • 5.5%

    The extra return investors want for owning shares instead of bonds.

    Default: a typical premium for Korean shares.

  • 5.51%

    The interest rate the company would pay to borrow.

    Default: the 10-year yield plus a 1.5% credit spread.

Starting point

Revenue (TTM to H1 2026)
₩513B
Net debt (borrowings and leases − cash and deposits)
₩85B
− Minority interests
₩21B
Shares
27,931,470
Share price
₩5,100
Market cap
₩142B

TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.

Past years and projection

Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.

FY2023FY2024FY2025Year 1Year 2Year 3Year 4Year 5
Revenue₩361B₩465B₩496B₩582B₩645B₩698B₩737B₩759B
Growth6.1%28.7%6.8%13.4%10.8%8.2%5.6%3.0%
EBIT₩19B₩13B₩257M₩29B₩32B₩34B₩36B₩37B
EBIT margin5.2%2.9%0.1%4.9%4.9%4.9%4.9%4.9%
After-tax EBIT₩14B₩9.7B₩186M₩21B₩23B₩25B₩26B₩27B
+ Depreciation₩12B₩16B₩18B₩20B₩23B₩24B₩26B₩27B
− Capital spending₩26B₩74B₩55B₩67B₩74B₩80B₩85B₩87B
− Working capital−₩46B₩36B−₩20B₩14B₩13B₩11B₩8.1B₩4.6B
Free cash flow₩46B−₩84B−₩17B−₩40B−₩42B−₩42B−₩41B−₩38B
Discount factor———0.9430.8890.8380.7900.745
Present value———−₩38B−₩37B−₩35B−₩32B−₩29B

Terminal value ₩530B, worth ₩395B today: 176% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.

Cross-check: what the market has paid before

For cyclical businesses, analysts check a DCF against the multiples the stock has traded at through past cycles. Price / book is the usual anchor for them: P/E looks highest at the bottom of a cycle, when earnings are smallest, and lowest at the top. The price each band would give today:

LowTypicalHigh
Price / book (book value ₩14,137 a share)Now 0.36×₩6,0660.43×₩9,0050.64×₩13,5690.96×
Price / earnings (last 12 months: ₩647 a share)Now 7.88×₩5,4508.42×₩8,57613.3×₩17,88327.6×
P/E on run-rate earnings (Q2 2026 × 4: ₩952 a share)Now 5.36×₩8,0158.42×₩12,61113.3×₩26,29627.6×

Low, typical and high are the 10th percentile, middle and 90th percentile of month-end multiples since 2021, each against the latest report out by then, per share at today's share count; loss years and P/E above 100 are left out. Run-rate earnings are one quarter × 4, not a forecast. Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.

Sensitivity

Fair value per share as two inputs change; the middle is the current case.

WACC ↓ · Terminal growth →1.0%1.5%2.0%2.5%3.0%
5.1%₩5,707₩7,381₩9,594₩12,660₩17,197
5.6%₩3,736₩4,963₩6,528₩8,596₩11,461
6.1%₩2,178₩3,100₩4,245₩5,704₩7,632
6.6%₩919₩1,627₩2,486₩3,550₩4,907
7.1%—₩439₩1,096₩1,892₩2,879

Now (TTM)

Market cap
₩142B
Enterprise value
₩228B
P/E
7.9×
P/B
0.4×
P/S
0.3×
EV/EBITDA
6.1×
Dividend yield
1.3%

Over time (at each year end)

20252024202320222021
Price₩6,250₩6,300₩10,270₩9,260₩14,600
Market cap₩175B₩176B₩287B₩259B₩408B
P/E20.1×31.6×10.5×12.7×22.8×
P/B0.5×0.5×0.8×0.7×1.2×
P/S0.4×0.4×0.8×0.8×1.4×
EV/EBITDA14.3×7.6×7.8×5.5×10.7×
Dividend yield1.0%2.9%———

Versus similar companies

CompanyP/EP/BP/SEV/EBITDADividend yield
Dongwha Pharm7.9×0.4×0.3×6.1×1.3%
Samsung Biologics34.7×8.2×15.1×—0.0%
Celltrion28.2×2.5×9.1×—0.0%
Alteogen76.3×27.5×58.0×—0.1%
SK biopharmaceuticals15.2×6.0×7.1×—0.0%
Yuhan23.3×2.3×2.4×30.4×0.8%
HLB—15.5×54.7×—0.0%
Similar companies (median)28.2×7.1×12.1×30.4×0.0%

Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.

Also known as: Dongwha Pharm / 동화약품 / 000020 / KRX:000020

Source: KRX statistical information